Medication Prior Authorization for GLP-1s and Specialty Drugs: How It Works

Updated November 5, 2026, based on CMS, the Code of Federal Regulations, the U.S. Code, NCPDP and UnitedHealthcare as of that date.

A medication prior authorization goes to whoever pays for the drug. For a prescription filled at a pharmacy, that's the pharmacy benefit: the Part D plan, the Medicaid pharmacy program or the plan's pharmacy benefit manager. For a drug given in the office, such as an infusion, it's usually the medical benefit. The two run on different forms, portals and deadlines, and the CMS prior authorization rule that set 7-day and 72-hour limits for medical services in 2026 excludes drugs.

For GLP-1s used for weight loss, there's an earlier question: does the plan cover the drug for that use at all? Federal law lets state Medicaid programs exclude weight loss drugs and leaves them out of Medicare Part D, and some commercial plans make weight loss coverage an option the employer elects. When coverage exists, a plan's criteria can ask for a BMI, any weight-related conditions, participation in a lifestyle program, and, at renewal, documented weight loss.

Pharmacy benefit or medical benefit

Start every medication request by working out which benefit pays.

• Pharmacy benefit: drugs the patient picks up at a retail, mail order or specialty pharmacy. Requests go to the plan or its PBM, through an electronic prior authorization in the EHR, a PBM portal, or a fax form.
• Medical benefit: drugs a clinician administers and the practice bills on a medical claim. Requests go through the health plan's medical prior authorization process, the same channel as procedures.

Some drugs can fall under either, depending on where they're given and how the plan set up its benefits. If you aren't sure, check the plan's drug list and medical policy, or call provider services and ask which benefit covers the drug in your setting.

Decision timeframes for drug prior authorizations

CMS's fact sheet on the Interoperability and Prior Authorization Final Rule says its policies don't apply to prior authorization decisions for drugs. Drug requests follow older, program-specific rules, and some of them are faster than the medical limits.

• Medicare Part D: 72 hours standard, 24 hours expedited (42 CFR 423.568 and 423.572)
• Medicare Advantage, Part B drugs: 72 hours standard, 24 hours expedited (42 CFR 422.568(b)(3) and 422.572(a)(2))
• Medicaid covered outpatient drugs: response within 24 hours, with a 72-hour emergency supply (Social Security Act 1927(d)(5))
• Employer group health plans: 15 days for pre-service claims, 72 hours for urgent care (29 CFR 2560.503-1)

A Part D plan must decide a standard coverage determination "no later than 72 hours after receipt of the request" under 42 CFR 423.568, and an expedited one within 24 hours under 42 CFR 423.572. The Medicare Advantage limits for Part B drugs in 42 CFR 422.568(b)(3) and 422.572 can't be extended.

For Medicaid, section 1927(d)(5) of the Social Security Act lets a state require prior authorization for a covered outpatient drug only if its system responds "within 24 hours of a request" and allows at least a 72-hour supply in an emergency. Medicaid managed care plans give notice on the same basis under 42 CFR 438.210(d)(3). Employer plans fall under 29 CFR 2560.503-1, with 15 days for a pre-service claim and 72 hours for urgent care.

Formulary exceptions start the clock later

Part D has one catch. When you ask for a formulary exception, such as coverage for a drug that isn't on the formulary, the 72-hour or 24-hour clock starts when the plan receives the prescriber's supporting statement, not when the request arrives. If no statement comes in within 14 calendar days, the clock runs from the end of those 14 days. Send the supporting statement with the request.

How electronic prior authorization works

Electronic prior authorization (ePA) for pharmacy benefit drugs uses the NCPDP SCRIPT standard. Medicare's Part D e-prescribing rule, 42 CFR 423.160, names these SCRIPT prior authorization transactions:

• PAInitiationRequest and PAInitiationResponse
• PARequest and PAResponse
• PAAppealRequest and PAAppealResponse
• PACancelRequest and PACancelResponse
• PANotification

NCPDP's overview of the SCRIPT ePA transactions describes the flow. In the solicited model, the prescriber's system sends a PAInitiationRequest for a patient and drug. The PBM or payer answers with the information it needs, as a question set, or says prior authorization isn't required. The prescriber sends a PARequest with the answers. The payer returns a status such as approved, denied, pended or more information required, and the exchange repeats if it needs more. In the unsolicited model, the prescriber skips the initiation step and sends information the trading partners agreed on in advance. A PACancelRequest stops a request that's still in process.

The question set is the clinical part of the request. NCPDP notes that the questions can carry coded references the EHR uses to pull answers from the patient's chart. Someone still has to review the answers and fill the gaps.

Two version notes. Under 45 CFR 170.205(b), adoption of SCRIPT version 2017071 expires on January 1, 2028, and version 2023011 is also adopted. In 2026, CMS proposed requiring Medicaid, CHIP and federal exchange plans to support NCPDP SCRIPT and two related standards beginning October 1, 2027, according to CMS's summary of the CMS-0062-P proposal. The August 2026 final rule finalized only the health IT API standards from that proposal and said comments on the rest are still under review. Check whether the payer requirements have been finalized before planning around them.

GLP-1s for weight loss: coverage comes first

Before you work on criteria, confirm the plan covers the drug for weight loss.

In Medicaid, section 1927(d)(2)(A) lists "agents when used for anorexia, weight loss, or weight gain" among the drugs a state may exclude or restrict. Coverage varies by state, so check the state's preferred drug list and prior authorization criteria.

In Medicare Part D, the definition of a covered Part D drug in section 1860D-2(e)(2)(A) leaves out drugs that Medicaid may exclude under 1927(d)(2), which includes weight loss agents. A Part D plan may still cover a GLP-1 for another approved use, such as type 2 diabetes. Weight loss coverage for Medicare patients now runs through a separate CMS program, covered below.

In commercial plans, weight loss coverage can be a benefit the employer chooses. UnitedHealthcare's 2026 weight loss prior authorization program, for example, describes itself as "an optional program" for clients that have elected to cover weight loss products with prior authorization.

What a plan's GLP-1 criteria look like

Criteria differ by plan, so read the plan's own policy. The UnitedHealthcare program above, effective October 1, 2026, shows the kinds of items plans can ask for. For initial approval of Wegovy or Zepbound for weight loss, it requires:

1. Age: over 16 for Zepbound, and 12 or older for Wegovy injection.
2. Use as an adjunct to lifestyle modification, such as dietary changes, exercise, behavioral support or a community-based program.
3. A BMI of 30 or more, or a BMI of 27 or more with a weight-related comorbidity such as dyslipidemia, hypertension, type 2 diabetes or sleep apnea.

The first approval lasts 5 months for Wegovy and 6 months for Zepbound. Reauthorization for Wegovy requires weight loss of at least 5% of baseline body weight plus continued lifestyle modification, and lasts 12 months. The policy allows a one-time 6-month authorization for patients still titrating to a maintenance dose. It also notes that state mandates and the member's benefit plan may change the criteria.

Those criteria tell you what to gather before you submit: a dated baseline weight and BMI, the comorbidity diagnosis, a note documenting the lifestyle program, and at renewal, the current weight against baseline. Build a template that pulls them into one place, because a reviewer can't approve what the notes don't state.

The Medicare GLP-1 Bridge

Medicare began covering certain GLP-1s for weight management on July 1, 2026, through the Medicare GLP-1 Bridge, a CMS demonstration that runs through December 31, 2027. CMS's information for Part D plans says it operates outside the Part D benefit and uses a single central processor for prior authorization, claims and pharmacy payment.

According to Medicare's weight loss drugs page and CMS's information for prescribers:

• Covered drugs are Foundayo tablets, Wegovy injection or tablets, and the Zepbound KwikPen. Single-dose Zepbound pens and vials aren't covered.
• The patient must be 18 or older with eligible Part D coverage and meet a BMI threshold: 35 or more; 30 or more with heart failure with preserved ejection fraction, uncontrolled hypertension or stage 3a or higher chronic kidney disease; or 27 or more with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease. Some plan types, such as private fee-for-service and PACE, aren't eligible unless the patient also has a standalone drug plan.
• Patients with type 2 diabetes, moderate to severe sleep apnea or MASH, and patients who already got a GLP-1 through their Part D plan, aren't eligible. Their requests go to the Part D plan.

The workflow is specific. The prescriber sends the prescription with an obesity diagnosis code from the E66 family and the note "SEND TO BRIDGE FOR WEIGHT MANAGEMENT." Without it, the pharmacy may send the claim to the Part D plan instead. Once the pharmacy submits the claim, the Bridge tells the pharmacy a prior authorization is needed, and the pharmacy sends the form to the prescriber, typically within 24 to 72 hours. If none arrives within 72 hours, the prescriber can download the fax form from CMS. The decision comes back within 72 hours of submission. An approval covers refills and dose changes through December 31, 2027, unless the patient switches to a different GLP-1. Only 28-day or 30-day fills are covered.

Psychiatric drugs and Part D protected classes

Part D treats six drug classes as classes of clinical concern under section 1860D-4(b)(3)(G)(iv): anticonvulsants, antidepressants, antineoplastics, antipsychotics, antiretrovirals, and immunosuppressants for transplant rejection. Under 42 CFR 423.120(b)(2)(vi), with CMS approval, a plan may apply prior authorization or step therapy to these drugs only for enrollees who aren't already on the therapy, and not to antiretrovirals.

For a practice managing psychiatric medications, that means a Part D patient who is stable on an antidepressant or antipsychotic generally shouldn't face a new prior authorization or step therapy requirement on that drug. A patient starting one can. Commercial and Medicaid plans set their own rules, so keep a payer-by-payer reference of where to submit and what each one asks.

Frequently asked questions

Is a pharmacy prior authorization the same as a coverage determination?

In Medicare Part D, a plan's denial of coverage for a drug and its decision on an exceptions request are coverage determinations under 42 CFR 423.566, with a 72-hour standard and 24-hour expedited limit under 42 CFR 423.568 and 423.572. Commercial plans and PBMs use their own terms and forms, so follow the plan's instructions.

Does Medicare cover Wegovy or Zepbound for weight loss?

From July 1, 2026, through December 31, 2027, Medicare covers Foundayo, Wegovy and the Zepbound KwikPen for weight management through the Medicare GLP-1 Bridge, for eligible patients with Part D. Medicare's weight loss drugs page lists a $50 monthly copayment. Patients with type 2 diabetes, moderate to severe sleep apnea or MASH go through their Part D plan instead.

What documentation do plans ask for on a GLP-1 prior authorization?

It depends on the plan. UnitedHealthcare's published criteria, for example, cover age, BMI, weight-related diagnoses, participation in a lifestyle program, and at renewal, weight loss measured against baseline. Read the plan's current policy before you submit.

How long does a GLP-1 approval last?

It varies by plan. UnitedHealthcare's 2026 program approves Wegovy for 5 months at first and 12 months at renewal. Under the Medicare GLP-1 Bridge, an approval lasts through December 31, 2027, unless the patient switches drugs.

Our prior authorization automation guide covers submitting requests and tracking decisions across payer portals, and our UnitedHealthcare portal automation guide covers authorizations in that portal.

Submitting medication prior authorizations across payer portals?

Champ automates portal work like submitting prior authorizations and checking their status. We set it up and run it, so your staff sees only the finished results. If GLP-1 and specialty drug requests are taking up your team's week, learn more here.

This post is general information, not legal, compliance or billing advice. Rules vary by payer, plan and state and change often, so confirm with the plan, PBM or state Medicaid agency before acting. Champ is not affiliated with or endorsed by CMS, Medicare, NCPDP, UnitedHealthcare or any other payer.